| |
| |
| Exchange: |
N/A |
| Security
Type: |
Common |
| Shares
Out: |
15,090,000 |
| Market
Cap: |
2.14(M) |
| Last
Volume: |
0 |
Avg
Vol: |
0 |
| 52
Week Range: |
$0.13 - $5.76 |
|
| Level
I Sector: |
N/A |
| Level
II Sector: |
N/A |
| Level
III Sector: |
N/A |
|
Member Indexes:
|
Rankings:
|
|
| Insider 3 Months : - |
| Insider 6 Months : - |
| Insider 3/6 Months : - |
|
| Guru Rank Number : - |
| Guru Rank Value : - |
| Guru Occurances : - |
|
|
|
|
|
| |
|
Company Profile Ampio Pharmaceuticals is a biopharmaceutical company focused on the research, development and improvement of immunomodulatory therapies for the treatment of pain from osteoarthritis. Ampion, Co.'s primary product candidate is a biologic drug, which contains ingredients that target several pathways in the innate immune response characteristic of inflammatory disease. Ampion is in development as an intra-articular injection treatment for severe Osteoarthritis of the Knee; an intravenous and inhaled treatment for COVID-19 patients; and an at-home inhalation treatment for patients with prolonged respiratory symptoms due to COVID-19.
|
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
|
3m +/-:
|
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
|
Actions:
|
|
|
| B |
Buy |
| S |
Sell |
| OE |
Option
Exercised |
| A |
Acquired |
| D |
Disposed |
| AB |
Automatic
Buy |
| AS |
Automatic
Sell |
| IO |
Initial
Ownership |
|
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
| |
| |
Summary (Direct Transactions Only)  |
3 Months |
6 Months |
12 Months |
24 Months |
| Total Shares Bought |
0 |
0 |
0 |
318,748 |
| Total Buy Value |
$0 |
$0 |
$0 |
$81,874 |
| Total People Bought |
0 |
0 |
0 |
3 |
| Total Buy Transactions |
0 |
0 |
0 |
8 |
| Total Shares Sold |
0 |
0 |
0 |
0 |
| Total Sell Value |
$0 |
$0 |
$0 |
$0 |
| Total People Sold |
0 |
0 |
0 |
0 |
| Total Sell Transactions |
0 |
0 |
0 |
0 |
| End Date |
2024-03-17 |
2023-12-15 |
2023-06-16 |
2022-06-16 |
|
| Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
  Coelho Philip H |
Director |
– • – |
2013-01-02 |
4 |
A |
$3.87 |
$10,000 |
D/D |
2,584 |
39,397 |
|
- |
|
| Giles Richard B |
Director |
– • – |
2013-01-02 |
4 |
A |
$3.87 |
$10,000 |
D/D |
2,584 |
175,076 |
|
- |
|
| Stevens David R |
Director |
– • – |
2013-01-02 |
4 |
A |
$3.87 |
$10,000 |
D/D |
2,584 |
4,852 |
|
- |
|
| Giles Richard B |
Director |
– • – |
2012-01-17 |
4 |
A |
$2.97 |
$50 |
I/I |
17 |
172,492 |
|
- |
|
| Giles Richard B |
Director |
– • – |
2012-01-17 |
4 |
A |
$2.97 |
$1,090 |
D/D |
367 |
172,475 |
|
- |
|
| Macaluso Michael |
Chief Executive Officer |
• • – |
2012-01-13 |
4 |
A |
$4.41 |
$10,002 |
D/D |
2,268 |
2,043,373 |
|
- |
|
| Coelho Philip H |
Director |
– • – |
2012-01-13 |
4 |
A |
$4.41 |
$10,002 |
D/D |
2,268 |
36,813 |
|
- |
|
| Stevens David R |
Director |
– • – |
2012-01-13 |
4 |
A |
$4.41 |
$10,002 |
D/D |
2,268 |
2,268 |
|
- |
|
| Giles Richard B |
Director |
– • – |
2012-01-13 |
4 |
A |
$4.41 |
$10,002 |
D/D |
2,268 |
172,108 |
|
- |
|
| Coelho Philip H |
Director |
– • – |
2011-11-22 |
4 |
S |
$7.98 |
$35,479 |
D/D |
(4,446) |
34,545 |
|
- |
|
| Coelho Philip H |
Director |
– • – |
2011-11-22 |
4 |
OE |
$1.03 |
$35,479 |
D/D |
34,446 |
38,991 |
|
- |
|
| Wingerter Donald B Jr |
Chief Executive OfficerOfficer |
• • – |
2011-05-18 |
3 |
IO |
$0.00 |
$0 |
D/D |
0 |
325,000 |
|
- |
|
| Giles Richard B |
Director |
– • – |
2011-05-18 |
3 |
IO |
$0.00 |
$0 |
D/D |
0 |
169,840 |
|
- |
|
| Bar-Or David |
Chief Scientific OfficerOffice |
• • – |
2011-05-18 |
3 |
IO |
$0.00 |
$0 |
D/D |
0 |
2,700,000 |
|
- |
|
| Macaluso Michael |
Director |
– • – |
2011-05-18 |
3 |
IO |
$0.00 |
$0 |
D/D |
0 |
2,041,105 |
|
- |
|
| Clift Vaughan Lennox |
Chief Regulatory AffairsOffice |
• – – |
2011-05-18 |
3 |
IO |
$0.00 |
$0 |
I/I |
0 |
575,000 |
|
- |
|
| Coelho Philip H |
Director |
– • – |
2011-05-18 |
3 |
IO |
$0.00 |
$0 |
D/D |
0 |
4,545 |
|
- |
|
| Mcgregor Mark D |
Chief Financial OfficerOfficer |
• – – |
2011-05-18 |
3 |
IO |
$0.00 |
$0 |
D/D |
0 |
20,000 |
|
- |
|
93 Records found
|
|
Page 4 of 4 |
|
|
0.01 (9.23%) 
